Optimi Health Corp.

OPTI

CA68405H1001

Other Specialty Retailers

Market Closed - Canadian Securities Exchange Other stock markets 03:59:49 2024-07-12 pm EDT			5-day change	1st Jan Change
0.305 ^CAD	-12.86%		-4.69%	+24.49%

Jun. 25	Optimi Health Up 7.8% as After Health Canada Go-Ahead to Supply MDMA and Psilocybin to Patients in Australia	MT
Jun. 11	Optimi Health Completes First International Shipment of MDMA to Israel and Secures CBSA Exporters Authorization ID	CI

Proactive: Optimi Health validates GMP process for MDMA capsules

May 15, 2024

Optimi Health Corp (CSE:OPTI, OTCQB:OPTHF) announced it received a Certificate of Analysis from an independent, third-party laboratory testing that confirms its formulated MDMA meets Good Manufacturing Practice (GMP) specifications.

The company said on Tuesday it had also completed GMP process validation for the encapsulation of the active pharmaceutical ingredient (API) in both 40mg and 60mg dosage formats for batch sizes up to 1,000 capsules during GMP production.

Full story here.

Attachments

Original Link
Permalink

Disclaimer

Optimi Health Corp. published this content on 16 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 May 2024 17:29:09 UTC.

Latest news about Optimi Health Corp.

Optimi Health Up 7.8% as After Health Canada Go-Ahead to Supply MDMA and Psilocybin to Patients in Australia	Jun. 25	MT
Optimi Health Completes First International Shipment of MDMA to Israel and Secures CBSA Exporters Authorization ID	Jun. 11	CI
Optimi Health Up 12% After Reporting Drug Establishment License From Health Canada	Jun. 03	MT
Optimi Health Corp. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 30	CI
Optimi Health Corp. Secures Import Permit from Mind Medicine Australia for Efficacy and Psilocybin Capsules	May. 29	CI
Optimi Health Corp. announced that it has received CAD 1.5 million in funding	May. 28	CI
Optimi Health to Be Sole Supplier of Psilocybin for ATMA Journey Centers Phase II Trial	May. 22	MT
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder	May. 22	CI
Optimi Health Receives Certificate of Analysis for Mdma 40Mg and 60Mg Gmp Capsules	May. 14	CI
Optimi Health Corp. Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research	May. 09	CI
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research	Apr. 23	CI
Optimi Health Corp. Completes In-House Production of MDMA Active Pharmaceutical Ingredient	Apr. 15	CI
Optimi Health Corp. Signs Psilocybin Supply Agreement with Matai Medical Research Institute	Apr. 09	CI
Optimi Health Corp. Receives Finished Product Test Results and Certificate of Analysis for GMP Natural Psilocybin Extract	Apr. 02	CI
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University	Mar. 26	MT
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University	Mar. 26	CI
Optimi Health Corp. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 29	CI
492,000 Warrants of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
606,000 Options of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
3,048,000 Common Share of Optimi Health Corp. are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
Optimi Health Notes Lykos Therapeutics and FDA Priority Review of New Drug Application	Feb. 12	MT
Optimi Health Corp. announced that it expects to receive CAD 1.5 million in funding	Feb. 07	CI
Optimi Health Corp. Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 28	CI
Optimi Health Secures Amendment to Increase Quantities of MDMA, MDA, and 2C-B	Jan. 19	MT
Optimi Health Granted Precursor Licence to Formulate MDMA, Completes Encapsulation Of Two Dosage Formats	Jan. 03	MT

Chart Optimi Health Corp.

Duration

Period

More charts

Company Profile

Optimi Health Corp. is an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances, such as 3,4-Methylenedioxymethamphetamine (MDMA), natural Manufacturing Practices (GMP)-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. The Company produces scalable psychedelic formulations for transformational human experiences. Its products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia. It is a supplier of drug and nutraceutical products. The Company works with customers, health food distributors, and drug developers, and patients regulated by Health Canada.

Sector

Other Specialty Retailers

Calendar

2024-08-08 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Health Food Stores

	1st Jan change	Capi.
OPTIMI HEALTH CORP.	+24.49%	20.75M
THE BETTER BEING CO.	-.--%	843M
DXN HOLDINGS BHD.	+0.79%	682M
NATURAL GROCERS BY VITAMIN COTTAGE, INC.	+45.31%	530M
ZINZINO AB	+21.31%	236M
MARX BIOTECH CO., LTD.	0.00%	153M
NANJING SINOLIFE UNITED COMPANY LIMITED	+217.39%	88.48M